« EMI is Buying Market Share | Main | Gone Kinda Fishing »
Latest Stories
- Excel Wankers and Recession Averages
- Sorry, New York is Closed. Check Back Later.
- Catching Falling 2009 Earnings Estimate Knife
- Survivorship Bias in Global Markets
- Talking Positions on a Lazy-ish Retirement Portfolio
April 3, 2007
The Trouble with Meteoric Rises
Good comment on "meteoric rises" over at the British Medical Journal. The topic is drug trials:The next trial carries the acronym METEOR from the initials of Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin – MEOIMTAEOR. Mmmm. I have never understood the expression “meteoric rise” since meteors can only fall – as this one does, flat on its face. It was funded by AstraZeneca to increase sales of rosuvastatin by showing that it decreased carotid intima-media thickness in individuals with mild increases, but it didn’t.[via BMJ]
Sphere It
| 
Digg it
| 
Bookmark it
| 
Stumble it
| 
Facebook it
Ah, failure at trials. That was one reason that the NEJM article did not mention in respect of small-molecule drugs. The difficulty in finding a drug that works for an apparently obvious target is a tough nut to crack.